Abstract
Breast cancer is one of the most common malignancies. However, the molecular mechanisms underlying its pathogenesis remain to be elucidated. The present study aimed to identify the potential prognostic marker genes associated with the progression of breast cancer. Weighted gene coexpression network analysis was used to construct free-scale gene coexpression networks, evaluate the associations between the gene sets and clinical features, and identify candidate biomarkers. The gene expression profiles of GSE48213 were selected from the Gene Expression Omnibus database. RNA-seq data and clinical information on breast cancer from The Cancer Genome Atlas were used for validation. Four modules were identified from the gene coexpression network, one of which was found to be significantly associated with patient survival time. The expression status of 28 genes formed the black module (basal); 18 genes, dark red module (claudin-low); nine genes, brown module (luminal), and seven genes, midnight blue module (nonmalignant). These modules were clustered into two groups according to significant difference in survival time between the groups. Therefore, based on betweenness centrality, we identified TXN and ANXA2 in the nonmalignant module, TPM4 and LOXL2 in the luminal module, TPRN and ADCY6 in the claudin-low module, and TUBA1C and CMIP in the basal module as the genes with the highest betweenness, suggesting that they play a central role in information transfer in the network. In the present study, eight candidate biomarkers were identified for further basic and advanced understanding of the molecular pathogenesis of breast cancer by using co-expression network analysis.
Highlights
The incidence of breast cancer continues to increase worldwide, and currently, breast cancer is a serious disease among women
Module eigengenes (MEs) of the black, dark red, brown, and midnight blue modules were found to have the highest correlation with the subtypes
In the era of precision medicine, there is an urgent need for better cancer-specific prognosis and progression biomarkers to provide accurate clinical information that could significantly enhance decision-making for patient management [20]
Summary
The incidence of breast cancer continues to increase worldwide, and currently, breast cancer is a serious disease among women. In 2017, the estimated number of new cases of invasive breast cancer was 252,710, among which 2470 men were diagnosed. 63,410 women were diagnosed with breast cancer in situ, and around 40,610 women and 460 men were expected to die of breast cancer. With the continuous efforts and progress of modern medicine, the treatment of breast cancer has become more effective, and the mortality rate of breast cancer has been significantly reduced. The recurrence and metastasis of breast cancer have still not been addressed comprehensively, and have become the greatest challenges in clinical treatment [3,4]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.